Loading the security overview…
Where the tokens are
| Quarter | Reported | EPS | EPS vs year ago | Revenue | Revenue vs year ago | Consensus EPS |
|---|---|---|---|---|---|---|
| Q2 FY26ended Jun 30, 2026 | Jul 23, 2026 | $0.42 | −25.0% | $1.74B | +13.6% | $0.74 |
| Q1 FY26ended Mar 31, 2026 | Apr 23, 2026 | $0.66 | +8.2% | $1.65B | +16.7% | $0.72 |
| Q4 FY25ended Dec 31, 2025 | — | $0.16 | −75.4% | $1.57B | +13.3% | — |
| Q3 FY25ended Sep 30, 2025 | — | $0.50 | −90.3% | $1.55B | +14.7% | — |
| Q2 FY25ended Jun 30, 2025 | — | $0.56 | −8.2% | $1.53B | +11.9% | — |
| Q1 FY25ended Mar 31, 2025 | — | $0.61 | +5.2% | $1.41B | +6.2% | — |
| Q4 FY24ended Dec 31, 2024 | — | $0.65 | +6.6% | $1.39B | +9.4% | — |
| Q3 FY24ended Sep 30, 2024 | — | $5.13 | +714.3% | $1.35B | +8.9% |
Growth compares each quarter with the same fiscal quarter a year earlier, and is left blank where that quarter is missing or its figure was zero or a loss. Consensus is the estimate published before each report. It usually refers to adjusted EPS, so it is shown beside the GAAP figure rather than subtracted from it: the difference would not be a beat or a miss.
Figures describe Edwards Lifesciences shares, not any token. As of Jul 23, 2026, from Massive's standardised financials and the earnings calendar.
| — |
| Q2 FY24ended Jun 30, 2024 | — | $0.61 | — | $1.37B | — | — |
| Q1 FY24ended Mar 31, 2024 | — | $0.58 | — | $1.33B | — | — |
| Q4 FY23ended Dec 31, 2023 | — | $0.61 | — | $1.27B | — | — |
| Q3 FY23ended Sep 30, 2023 | — | $0.63 | — | $1.24B | — | — |